Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease After at Least 2 Lines of Systemic Therapy

NCT06263478 is registered in ClinicalTrials.gov with Incyte Biosciences Japan GK as lead sponsor.

NCT NCT06263478
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06263478 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease After at Least 2 Lines of Systemic Therapy
Lead sponsor
Incyte Biosciences Japan GK
Phase
Phase 3
Overall status
Active, not recruiting
Start date
July 30, 2024
Completion date
March 30, 2027
Enrollment
21 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

chronic graft-versus-host-disease